Deferoxamine and eflornithine (DL-alpha-difluoromethylornithine) in a rat model of Pneumocystis carinii pneumonia | Zendy

A B Clarkson | Zendy; Muhamed Sarić | Zendy; R W Grady | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Deferoxamine and eflornithine (DL-alpha-difluoromethylornithine) in a rat model of Pneumocystis carinii pneumonia

Author(s) -

A B Clarkson,

Muhamed Sarić,

R W Grady

Publication year - 1990

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.34.9.1833

Subject(s) - eflornithine , pneumocystis carinii , deferoxamine , pneumonia , enzyme inhibitor , medicine , pharmacology , biology , microbiology and biotechnology , ornithine decarboxylase , enzyme , biochemistry , pneumocystis jirovecii

The iron chelator deferoxamine and the polyamine biosynthesis inhibitor eflornithine (DL-alpha-difluoromethylornithine) were examined for anti-Pneumocystis carinii activity in the rat model of P. carinii pneumonia. The activity of deferoxamine at 250, 500, and 1,000 mg/kg given intraperitoneally provides evidence that iron chelation is a promising novel approach to P. carinii chemotherapy. Results with eflornithine at 2, 3, and 4% in drinking water confirm and extend previously reported activity in the rat model.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research